

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **PROPOSED CHANGE OF AUDITOR**

This announcement is made by the board of directors (the “**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board announces that due to the needs of business development and the audit of the Company and in accordance with the “Guidance on Standardizing the Procurement Behavior of Municipal State-owned Enterprises” (《關於規範市屬國有企業採購行為的指導意見》) issued by the State-owned Assets Supervision and Administration Commission of Guangzhou Municipal People’s Government and the internal control requirements and procedures of the Company, the Company conducted the selection of the financial auditor of the Company for year 2022 and the auditor of the Company for internal control for year 2022. According to the result of selection and with the recommendation of the audit committee of the Company, the Board resolved to propose the appointment of WUYIGE Certified Public Accountants LLP\* (大信會計師事務所(特殊普通合夥)) (“**WUYIGE**”) as both the auditor of the Company for year 2022 and the internal control auditor of the Company for year 2022 to replace BDO China Shu Lun Pan Certified Public Accountants LLP\* (立信會計師事務所(特殊普通合夥)) (“**BDO**”). The proposed appointment of WUYIGE as both the auditor of the Company for year 2022 and the internal control auditor of the Company for year 2022 is subject to the approval of the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company to be held on 26 May 2022.

BDO has confirmed in writing that up to the issue of its confirmation, there are no matters in relation to the change of auditor that need to be brought to the attention of the Shareholders. The Board is not aware of any matters in relation to the proposed change of auditor that needs to be brought to the attention of the Shareholders. The Board and the audit committee of the Company have also confirmed that there are no disagreements or outstanding matters between the Company and BDO.

A supplemental circular containing, among other things, further details of the proposed appointment of the new 2022 auditor of the Company, together with the supplemental notice of the annual general meeting, will be dispatched to the Shareholders as soon as practicable.

The Board would like to express its sincere gratitude to BDO for the professional and quality services rendered to the Company during their service period.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 26 April 2022

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive Directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin and Mr. Huang Min as independent non-executive Directors.*